Ads
related to: is plan b fda approved drug for macular degenerationdoconsumer.com has been visited by 100K+ users in the past month
Search results
Results from the WOW.Com Content Network
Pegaptanib [2] sodium injection (brand name Macugen) is an anti-angiogenic medicine for the treatment of neovascular (wet) age-related macular degeneration (AMD). [3] It was discovered by NeXstar Pharmaceuticals (which merged with Gilead Sciences in 1999) and licensed in 2000 to EyeTech Pharmaceuticals, now OSI Pharmaceuticals, for late stage development and marketing in the United States.
The FDA approved two biosimilars for Eylea (aflibercept), a drug used to treat age-related macular degeneration, diabetic retinopathy and other eye conditions.
Conbercept, sold under the commercial name Lumitin, is a novel vascular endothelial growth factor (VEGF) inhibitor used to treat neovascular age-related macular degeneration (AMD) [1] [2] and diabetic macular edema (DME). [3] The anti-VEGF was approved for the treatment of neovascular AMD by the China State FDA (CFDA) in December 2013.
By May 2012, anti-VEGF treatment with Avastin has been accepted by Medicare, is quite reasonably priced, and effective. Lucentis has a similar but smaller molecular structure to Avastin, and is FDA-approved (2006) for treating MacD, yet remains more costly, as is the more recent (approved in 2011) aflibercept (Eylea). Tests on these treatments ...
The "plan B" morning-after pill is a type of emergency birth control, also called emergency contraception, according to the Mayo Clinic, which said it can help prevent pregnancy after sexual ...
The folks at Regeneron Pharmaceuticals (NAS: REGN) are going to have a happy weekend right before they settle down for Thanksgiving. Tarrytown, N.Y.-based Regeneron said yesterday it has gotten ...
Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment created from the same parent mouse antibody as bevacizumab.It is an anti-angiogenic [16] that is approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion.
Faricimab, sold under the brand name Vabysmo (/ v ə ˈ b aɪ z m oʊ / və-BYEZ-mow), is a monoclonal antibody used for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).
Ads
related to: is plan b fda approved drug for macular degenerationdoconsumer.com has been visited by 100K+ users in the past month